Advertisement
EDIT vs SANA
Which Stock Would AI Choose? Editas Medicine (EDIT) vs. Sana Biotechnology (SANA) Stock Comparison
Key Takeaways
- EDIT (Editas Medicine) and SANA (Sana Biotechnology) are both clinical-stage biotechnology companies, yet they pursue distinct technologies: EDIT focuses on CRISPR gene editing, while SANA centers on engineered "hypoimmune" cell therapies.
- EDIT's lead candidate, EDIT-401, recently received clearance to begin a Phase 1/2 trial in Australia for high cholesterol (heterozygous familial hypercholesterolemia), a milestone that has shaped its recent momentum.
- SANA's pipeline leans on SC451 for type 1 diabetes and SG293 for B-cell diseases, with proof-of-concept data expected over the next 12 to 18 months.
- EDIT ended its most recent quarter with roughly $211.6 million in cash and a runway into the second half of 2028, while SANA held about $160.5 million with a comparatively shorter runway and higher dilution concerns.
- Both stocks carry elevated risk, but analyst sentiment skews more decisively positive on SANA (a Strong Buy consensus), whereas EDIT draws a more mixed mix of Buy and Hold ratings.
- For deeper context on each company, visit the dedicated EDIT Major News and EDIT Today's Price Move pages, as well as SANA Major News and SANA Today's Price Move.
- To see how automated strategies are positioning across the market, explore Trending AI Robots.
Introduction
Editas Medicine (EDIT) and Sana Biotechnology (SANA) are two early-stage names in the genetic medicine and engineered-cell therapy space that frequently attract the same speculative, growth-oriented investors. Although neither company has a marketed product, both are advancing toward human data that could redefine their valuations. This stock comparison examines their relative performance, market positioning, and catalysts to help traders and investors assess how these two high-volatility biotechnology stocks differ. The comparison is particularly relevant for those weighing a CRISPR-focused platform against a cell-engineering approach to type 1 diabetes and B-cell diseases.
EDIT Overview and Recent Performance
EDIT, or Editas Medicine, develops gene-editing therapies built on CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology, including Cas9 and Cas12 systems. After discontinuing its earlier reni-cel sickle cell program and restructuring, the company has refocused its pipeline on EDIT-401, an investigational one-time, in vivo (inside the body) gene-editing therapy targeting the LDLR gene for heterozygous familial hypercholesterolemia, an inherited condition marked by dangerously elevated LDL ("bad") cholesterol.
In recent weeks, EDIT's market positioning has improved following clearance to begin a Phase 1/2 clinical trial of EDIT-401 in Australia, its first move into human testing for the program. Preclinical data showed mean LDL cholesterol reductions of roughly 90% or more in non-human primates, supporting analyst enthusiasm. Financially, the company reported a narrower-than-expected quarterly loss with collaboration revenue of about $11.9 million, and its cash position of approximately $211.6 million is expected to fund operations into the second half of 2028. These developments, along with an analyst upgrade to Buy, have contributed to a more constructive relative performance in recent trading.
SANA Overview and Recent Performance
SANA, or Sana Biotechnology, engineers cells to treat serious diseases, using its Hypoimmune (HIP) platform designed to create cells that evade the immune system and can be transplanted without immunosuppression. Its lead programs include SC451, a stem-cell-derived pancreatic islet cell therapy for type 1 diabetes, and SG293, an in vivo CAR T (chimeric antigen receptor T-cell) approach for B-cell-related diseases. Earlier data from its UP421 program, published in the New England Journal of Medicine, showed transplanted beta cells surviving without immunosuppression in a single patient.
Recent market activity for SANA has been shaped by cost discipline and pipeline milestones. The company reported a narrowed quarterly net loss of roughly $63.6 million, down from about $93.8 million a year earlier, as it scaled back internal manufacturing and leaned on third-party CDMOs (contract development and manufacturing organizations). SANA held approximately $160.5 million in cash at the end of the quarter. While management has pointed to proof-of-concept data expected over the next 12 to 18 months, a comparatively short cash runway and the possibility of future equity raises remain central concerns influencing sentiment.
Trending AI Robots
For traders who prefer a systematic approach, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only those best suited to current market conditions are featured in this section. These bots vary widely in trading style, strategy, timeframe, performance, and the set of tickers they trade, giving investors a broad menu of automated approaches. Many bots publish detailed statistics, including historical win rates and trade counts, so users can evaluate them on observable metrics rather than marketing claims. Browsing the Trending AI Robots selection is a practical way to see how automation is adapting to shifting conditions across stocks like EDIT and SANA.
Head-to-Head Comparison
The two companies diverge sharply in business model despite their shared biotechnology label. EDIT is concentrated on a single CRISPR-based asset targeting a large cardiometabolic indication, which creates a high-concentration, catalyst-driven profile centered on EDIT-401 trial progress. SANA operates a broader platform spanning type 1 diabetes, oncology, and autoimmune disease, which offers multiple shots on goal but also spreads resources across more programs.
On growth drivers, EDIT's momentum leans on a recently cleared clinical trial and strong preclinical lipid-lowering data, while SANA's narrative depends on near-term human proof-of-concept results. Risk profiles also differ: EDIT benefits from a longer cash runway into the second half of 2028, whereas SANA faces more pressing funding and dilution questions despite a more bullish analyst consensus. Sector exposure is similar — both are sensitive to biotech-sector sentiment and interest-rate expectations — but market sentiment currently prices SANA with a Strong Buy consensus and higher average price targets, while EDIT garners a more mixed, though increasingly positive, view.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst proximity, and balance-sheet stability, Tickeron's AI would likely view EDIT and SANA through different lenses. EDIT's recently cleared clinical trial, longer cash runway, and a catalyst pathway into 2027 suggest a comparatively clearer near-term narrative, which may favor trend consistency. SANA's broader pipeline and stronger analyst consensus offer potentially greater upside but carry more pronounced funding uncertainty. Accordingly, the AI would probably lean toward EDIT on the basis of relative stability and a defined, near-term clinical catalyst, while acknowledging that SANA's multi-program platform could command greater attention if upcoming proof-of-concept data proves positive. This assessment is probabilistic rather than definitive and is not a recommendation to trade either security.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and SANA is a Hold.
EDIT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for EDIT turned positive on October 27, 2026. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 48 cases where EDIT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
SANA's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for SANA turned positive on October 26, 2026. Looking at past instances where SANA's MACD turned positive, the stock continued to rise in 37 of 41 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SANA's RSI Indicator exited the oversold zone, 35 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +5.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where SANA advanced for three days, in 186 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SANA as a result. In 71 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SANA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
SANA broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SANA entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.590) is normal, around the industry mean (3.498). P/E Ratio (-3.160) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. SANA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SANA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
EDIT | ||
|---|---|---|
OUTLOOK RATING 1..100 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 53 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 58 | |
P/E GROWTH RATING 1..100 | 30 | |
SEASONALITY SCORE 1..100 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| EDIT | SANA | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 88% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 85% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 89% |
| Advances ODDS (%) | 3 days ago 80% | 3 days ago 79% |
| Declines ODDS (%) | 10 days ago 90% | 10 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 88% | 1 day ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EDIT’s FA Score shows that 1 FA rating(s) are green while SANA’s FA Score has 1 green FA rating(s).
- EDIT’s FA Score: 1 green, 4 red.
- SANA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EDIT’s TA Score shows that 2 TA indicator(s) are bullish while SANA’s TA Score has 4 bullish TA indicator(s).
- EDIT’s TA Score: 2 bullish, 7 bearish.
- SANA’s TA Score: 4 bullish, 4 bearish.
Price Growth
EDIT (@Biotechnology) experienced а -3.65% price change this week, while SANA (@Biotechnology) price change was -0.41% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was -3.33%, and the average quarterly price growth was -13.61%.
Reported Earning Dates
EDIT is expected to report earnings on Feb 25, 2027.
SANA is expected to report earnings on Mar 23, 2027.
Industries' Descriptions
@Biotechnology (+4.22% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
SANA and
Correlation & Price change
A.I.dvisor indicates that over the last year, SANA has been loosely correlated with EDIT. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if SANA jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To SANA | 1D Price Change % | ||
|---|---|---|---|---|
| SANA | 100% | -1.42% | ||
| EDIT - SANA | 59% Loosely correlated | -8.91% | ||
| CRSP - SANA | 58% Loosely correlated | -9.77% | ||
| RCKT - SANA | 56% Loosely correlated | -3.16% | ||
| BEAM - SANA | 56% Loosely correlated | -6.92% | ||
| MGTX - SANA | 55% Loosely correlated | +1.37% | ||
More | ||||